ABSTRACT
El diagnóstico de enfermedad de Parkinson (ED) se basa en las principales manifestaciones motoras: bradicinesia en combinación con temblor en reposo, rigidez o ambos. Cuando se realiza el diagnóstico basado en la sintomatología motora clínica típica ya se han perdido hasta el 60 % de las neuronas dopaminérgicas de la sustancia negra pars compacta mesencefálica. La identificación de los síntomas premotores son un marcador temprano para sospechar la aparición futura de la enfermedad, así como su progresión y gravedad. La hipótesis sobre la patogénesis que mejor expone la progresión de la enfermedad es la teoría de Braak. Esta se basa en la aparición y presencia de cuerpos de Lewy en diferentes estructuras anatómicas, las cuales representadas en cada uno de sus seis estadios y podrían ser la explicación biológica de los síntomas premotores, motores y no motores. La detección temprana de los síntomas premotores puede tener repercusiones positivas en el enfoque, seguimiento, diagnóstico y tratamiento de la EP. El propósito de este artículo es identificar las aproximaciones neurológicas descritas por la teoría de Braak para los síntomas premotores de la enfermedad de Parkinson de acuerdo con la literatura publicada en los últimos 20 años.
The diagnosis of Parkinson's disease (PD) is based on the main motor manifestations: bradykinesia in combination with tremor at rest, rigidity, or both. When the diagnosis is made based on typical clinical motor symptoms, up to 60 % of the dopaminergic neurons of the mesencephalic substantia nigra pars compacta have already been lost. The identification of premotor symptoms is an early marker to suspect the future appearance of the disease, as well as its progression and severity. The hypothesis about the pathogenesis that best exposes the progression of the disease is Braak's theory. It is based on the appearance and presence of Lewy bodies in different anatomical structures, which are represented in each of its six stages and could be the biological explanation biological of premotor, motor, and non-motor symptoms. Early detection of premotor symptoms can have positive repercussions in the approach, follow-up, diagnosis and treatment of PD. The purpose of this article is to identify the neurological approaches described by Braak's theory for the premotor symptoms of Parkinson's disease according to the literature published in the last 20 years.
O diagnóstico da doença de Parkinson (DP) baseia-se nas principais manifestações motoras: bradicinesia combinada com tremor de repouso, rigidez ou ambos. Quando o diagnóstico é feito com base em sintomas clínicos motores típicos, até 60% dos neurônios dopaminérgicos da substância negra pars compacta mesencefálica já foram perdidos. A identificação de sintomas pré-motores é um marcador precoce para suspeitar do futuro aparecimento da doença, bem como da sua progressão e gravidade. A hipótese sobre a patogênese que melhor expõe a progressão da doença é a teoria de Braak. Isto se baseia no aparecimento e presença de corpos de Lewy em diferentes estruturas anatômicas, que estão representados em cada uma de suas seis etapas e podem ser a explicação biológica dos sintomas pré-motores, motores e não motores. A detecção precoce de sintomas pré-motores pode repercutir positivamente na abordagem, acompanhamento, diagnóstico e tratamento da DP. O objetivo deste artigo é identificar as abordagens neurológicas descritas pela teoria de Braak para os sintomas pré-motores da doença de Parkinson de acordo com a literatura publicada nos últimos 20 anos.
Subject(s)
Humans , Adult , Middle Aged , Aged , Aged, 80 and overABSTRACT
La enfermedad de Parkinson y Alzheimer son las enfermedades neurodegenerativas más frecuentes a nivel mundial. Tienen etiología multifactorial, entre ellas, la genética; y son motivo de interés en la investigación científica actual. Se realizó una revisión narrativa con el objetivo de determinar las alteraciones genéticas asociadas a estas patologías, además su influencia en la evolución y respuesta al tratamiento de ellas. Se consultaron artículos originales, revisiones bibliográficas, sistemáticas, metaanálisis en inglés y español, con fecha de publicación entre el 1 enero de 2018 y el 20 de mayo de 2023, en bases como PubMed y Medline. Se utilizaron los términos MeSH «Alzheimer Disease¼, «Parkinson Disease¼, «Drug Therapy¼ y «Mutations¼. El riesgo hereditario para la enfermedad de Parkinson suele ser poligenético, sin embargo, existen genes relacionados con mutaciones monogénicas. Se identifican alteraciones en genes de α-sinucleína, glucocerebrosidasa y quinasa 2 rica en leucina que se relacionan con mayor riesgo de desarrollar Parkinson, además de variaciones en el cuadro clínico y edad de inicio de síntomas. En cuanto a la enfermedad de Alzheimer, las alteraciones en los genes de la proteína precursora amiloide, presenilina 1 y 2 se relacionan con la forma familiar de la enfermedad; por otra parte, las de apolipoproteína E4 se han identificado en la forma esporádica, por lo que se consideran como el factor de riesgo genético más importante para su desarrollo
Parkinson's and Alzheimer's are the most frequent neurodegenerative diseases worldwide. They have a multifactorial etiology, including genetics, and are of interest in current scientific research. A narrative review was carried out with the aim of determining the genetic alterations associated with these pathologies, as well as their influence on their evolution and response to treatment. Original articles, literature reviews, systematic reviews, meta-analyses in English and Spanish, with publication date between January 1, 2018 and May 20, 2023, were consulted in databases such as PubMed and Medline. MeSH terms "Alzheimer Disease", "Parkinson Disease", "Drug Therapy" and "Mutation" were used. Hereditary risk for Parkinson's disease is usually polygenetic, however, there are genes related to monogenic mutations. Alterations in α-synuclein, glucocerebrosidase and leucine-rich kinase 2 genes have been identified that are related to an increased risk of developing Parkinson's disease, in addition to variations in the clinical picture and age of symptom onset. As for Alzheimer's disease, alterations in the genes of the amyloid precursor protein, presenilin 1 and 2 are related to the familial form of the disease; on the other hand, those of apolipoprotein E4 have been identified in the sporadic form, and are therefore considered to be the most important genetic risk factor for its development
Subject(s)
El SalvadorABSTRACT
Abstract Introduction Advanced Glycation End-Products (AGEs) are a diverse group of highly reactive molecules that play a vital role in the development of neurodegenerative disorders, such as Parkinson's Disease (PD), leading to a decline in functional and cognitive capacity. The objective of this study was to assess the intake and quantification of AGEs in individuals with PD and to correlate them with their functional and cognitive abilities. Methods This was a cross-sectional study involving 20 PD patients and 20 non-PD individuals as the Control group (C). The autofluorescence reader was used to evaluate skin AGEs, while food recall was used to quantify AGEs consumed for three different days. The Montreal Cognitive Assessment, Short Physical Performance Battery, and handgrip tests were used. PD patients demonstrated greater impairment in functional capacity compared to the control group. Results Dominant Handgrip (p = 0.02) and motor performance, in the sit and stand test (p = 0.01) and Short Physical Performance Battery (SPPB) (p = 0.01) were inferior in PD patients than the control group. Although PD patients tended to consume less AGEs than the control group, AGE intake was negatively correlated with handgrip strength in individuals with PD (r = -0.59; p < 0.05). Conclusion PD patients had lower strength and functional capacity, suggesting that the effects of AGEs might be exacerbated during chronic diseases like Parkinson's.
ABSTRACT
Abstract Background Therapeutic adherence is a decisive issue on chronic disease management in patients requiring long-term pharmacotherapy, such as Parkinson's disease (PD). Although it is well known that socioeconomic factor is a barrier to medication adherence in many chronic diseases, its impacts on PD still need to be investigated. Objective Explore what and how socioeconomic factors impact medication adherence in people with PD. Methods We carried out a scoping review across three databases to identify studies exploring what and how socioeconomic factors impact medication adherence in people with PD considering eight attributes: 1. educational level, 2. disease-related knowledge, 3. income, 4. cost of medication, 5. drug subsidy (meaning presence of subsidies in the cost of medication), 6. employability, and 7. ethnicity (black, indigenous, immigrants). Results Of the 399 identified studies (Embase = 294, Medline = 88, LILACS = 17), eight met inclusion criteria. We identified factors covering the eight attributes of socioeconomic impact, and all of them negatively impacted the medication adherence of people with PD. The most prevalent factor in the studies was low patient educational level (four studies), followed by costs of medications (three studies), income (three studies), and disease-related knowledge (three studies). Distinctly from most of the studies selected, one of them evidenced suboptimal adherence in individuals receiving the medication free of charge, and another one could not find correlation between suboptimal adherence and educational level. Conclusion Socioeconomic factors negatively impact medication adherence in PD patients. This review provides basis for developing patient and population-based interventions to improve adherence to treatment in PD.
Resumo Antecedentes A adesão à medicação é um componente crucial no manejo correto da doença de Parkinson (DP) e, embora esteja bem estabelecido que o fator socioeconômico é uma barreira à adesão medicamentosa em muitas doenças crônicas, seus impactos na DP ainda precisam ser investigados. Objetivo Explorar quais são e como os fatores socioeconômicos afetam a adesão à medicação em pessoas com DP. Métodos Realizamos uma revisão de escopo em três bases de dados para identificar estudos que explorassem quais e como os fatores socioeconômicos impactam na adesão à medicação em pessoas com DP, considerando oito atributos: 1. nível educacional, 2. conhecimento relacionado à doença, 3. renda, 4. custo de medicamentos, 5. subsídio de medicamentos (ou seja, presença de subsídios no custo dos medicamentos), 6. empregabilidade e 7. etnia (negra, indígena, imigrantes). Resultados Dos 399 estudos identificados (Embase = 294, Medline = 88, LILACS = 17), oito preencheram os critérios de inclusão. Identificamos fatores que abrangem os oito atributos de impacto socioeconômico e todos impactaram negativamente na adesão medicamentosa de pessoas com DP. Foram mais prevalentes o baixo nível educacional do paciente (quatro estudos), custos dos medicamentos, nível de renda e conhecimento relacionado à doença (três estudos cada). Diferentemente da maioria dos estudos selecionados, um deles evidenciou adesão subótima em indivíduos que receberam a medicação gratuitamente, e outro não encontrou correlação entre adesão subótima e nível educacional. Conclusão Fatores socioeconômicos impactam negativamente a adesão ao tratamento medicamentoso em pessoas com DP. Esta revisão fornece base para o desenvolvimento de intervenções baseadas em pacientes e populações no intuito de melhorar a adesão ao tratamento farmacológico de pessoas com DP.
ABSTRACT
Abstract Background The early identification of risk for dysphagia in patients with Parkinson's disease (PD) is essential for the prevention of nutritional and pulmonary complications. Objective To analyze the sensitivity and specificity of the Swallowing Disturbance Questionnaire (SDQ-PD) and the Eating Assessment Tool (EAT-10) in identifying dysphagia risk in patients with early and intermediate stages of PD. Methods Twenty-nine patients with PD participated in the study. EAT-10 and SDQ-PD questionnaires were applied, and a videofluoroscopic swallowing study. Dysphagia Outcome and Severity Scale (DOSS) was used to classify the presence and severity of dysphagia, and the Penetration-Aspiration Scale (PAS) was used to identify the presence of penetration/aspiration. In the statistical analysis, the sensitivity and specificity of the risk questionnaires were calculated, as well as positive predictive value, negative predictive value, and accuracy. Results EAT-10 to identify the risk of penetration/aspiration revealed a sensitivity of 71.42% and specificity of 45.45%; in the identification of the presence of dysphagia, the sensitivity was 47.61%, and the specificity was 12.5%. The SDQ-PD questionnaire for risk of penetration/aspiration demonstrated a sensitivity of 28.57%, and a specificity of 68.18%. In terms of identifying the presence of dysphagia, the sensitivity was 20%, while the specificity was 44.44%. Conclusion The SDQ-PD revealed low sensitivity and low specificity to identify the presence of dysphagia and/or penetration/aspiration in patients with early and intermediate stages of PD in this sample. Despite its low specificity, the EAT-10 exhibited good sensitivity in indicating the risk of penetration/aspiration.
Resumo Antecedentes A identificação precoce de risco para disfagia nos pacientes com doença de Parkinson (DP) é fundamental para a prevenção de complicações nutricionais e pulmonares. Objetivo Analisar a sensibilidade e especificidade dos questionários Swallowing Disturbance Questionnaire (SDQ-PD) e Eating Assessment Tool (EAT-10) para a identificação do risco de disfagia em pacientes com DP nos estágios iniciais e intermediários da doença. Métodos Participaram 29 pacientes com DP. Foi realizado a aplicação dos questionários EAT-10 e SDQ-PD e o exame de videofluoroscopia da deglutição. Para a classificação da presença e gravidade da disfagia foi utilizada a escala Dysphagia Outcome and Severity Scale e, para identificação da presença de penetração/aspiração, a escala Penetration-Aspiration Scale (PAS). Na análise estatística, calcularam-se a sensibilidade e a especificidade dos questionários de risco EAT-10 e SDQ-DP e o valor preditivo positivo, o valor preditivo negativo e a acurácia. Resultados A análise do EAT-10 para identificar o risco de penetração/aspiração revelou sensibilidade de 71.42% e especificidade de 45.45%; para identificar a presença de disfagia, a sensibilidade foi de 47,61% e a especificidade de 12.5%. Em relação ao questionário SDQ-PD, para identificar risco de penetração/aspiração, a sensibilidade foi de 28.57% e a especificidade de 68.18% e, para identificar a presença de disfagia, a sensibilidade foi de 20% e a especificidade de 44.44%. Conclusão O questionário SDQ-PD revelou baixa sensibilidade e baixa especificidade para identificar presença de disfagia e/ou penetração/aspiração em pacientes com DP em estágios iniciais e intermediários para essa amostra. O EAT-10 revelou boa sensibilidade na indicação de risco de penetração/aspiração, apesar de baixa especificidade.
ABSTRACT
Parkinson's disease （PD） is a kind of chronic progressive neurodegenerative disease that has a high prevalence rate in recent years， especially in the elderly. PD belongs to the category of "tremor disease" and "tremor" in traditional Chinese medicine， and Tianma Goutengyin is a classic prescription contained in the Synopsis of The New Significance of Patterns and Treatment in Miscellaneous Diseases（《中医内科杂病证治新义》）. This article explored the theory of Tianma Goutengyin in the treatment of PD， and based on network pharmacological research， the article summarized relevant research on Tianma Goutengyin and its single herb in the treatment of PD. Moreover， it discussed the clinical applications and mechanisms of Tianma Goutengyin and its single herb in the treatment of PD. It is found that the mechanisms of Tianma Goutengyin in treating PD may be related to resisting oxidative stress， inhibiting inflammatory response， regulating neurotransmitters， and protecting dopamine （DA） neurons. Besides， the main components of the single herb in Tianma Goutengyin for treating PD are gastrodin， rhynchophylline， geniposide， gardenial alcohol， eucommitol glycoside， motherwort alkaloid， baicalin， pachyman， and achyranthes bidentata sterol. They can improve the related symptoms of PD patients by inhibiting inflammatory response， resisting oxidative stress， affecting calcium ion concentration， restoring mitochondrial function， and and protecting DA neurons. This article summarized the research progress of Tianma Goutengyin and its single herb in treating PD， so as to provide a reference for the prescription and medication of Tianma Goutengyin in the treatment of PD and subsequent research on the mechanisms of Tianma Goutengyin and its single herb in the treatment of PD and give play to the advantages of traditional Chinese medicine in the treatment of PD.
ABSTRACT
The syndrome differentiation of Yin and Yang has the function of controlling the other six principles in the eight principles syndrome differentiation，which is a higher level or general induction of the disease. In the clinical process of traditional Chinese medicine，syndrome differentiation of Yin and Yang runs through the whole process of disease diagnosis and treatment. For Parkinson's disease，syndrome differentiation of Yin and Yang is particularly important. Different symptoms，the transformation of pathogenesis during the development of the disease and the treatment of traditional Chinese and western medicine all reflect the characteristics of Yin and Yang opposition restriction，mutual root and mutual use，and the transformation of ebb and flow. This article discusses the background，application and value of Yin-Yang syndrome differentiation from three aspects：the origin and application of yin-yang syndrome differentiation，the basis of Parkinson's disease syndrome differentiation，and the status and role of Yin-Yang syndrome differentiation in Parkinson's disease. It is of great significance to guide the diagnosis and treatment of Parkinson's disease with "Yin-Yang as the key point".
ABSTRACT
Objective: To examine laryngeal maximum performance through a novel pitch diadochokinetic (DDK) task in people with Parkinson's disease (PD) and healthy controls. Methods: This exploratory pilot study included a total of eight people with PD (seven male and one female) and eight healthy controls. Participants were instructed to rapidly transition or alternate between a chosen comfortable low and high pitch and were instructed to complete the task as a pitch glide. An Auditory Sawtooth Waveform Inspired Pitch Estimator-Prime model was used to first extract the pitch contour and then a customized MATLAB algorithm was used to compute and derive measures of pitch range and pitch slope. Results: Pitch range and slope were reduced in some participants with PD. Effects of age and disease duration were observed in people with PD: reductions in both pitch measures with increase in age and disease duration. Conclusions: A novel pitch DDK task may supplement the conventional laryngeal DDK task in the evaluation and treatment of motor speech and voice disorders. Individual variability analysis may provide specific diagnostic and therapeutic insights for people with PD.
Objetivo: Examinar el máximo rendimiento laríngeo a través de una novedosa tarea diadococinética de tono (DDK, por sus siglas en inglés) en personas con enfermedad de Parkinson (EP) y controles sanos. Métodos: Este estudio piloto exploratorio incluyó un total de ocho personas con EP (siete hombres y una mujer) y ocho controles sanos. Se instruyó a los participantes para que hicieran una transición rápida o alternaran entre un tono bajo y uno alto que les resultara cómodo y se les indicó que completaran la tarea como un deslizamiento de tono. Se utilizó un modelo de Estimador de Tono Inspirado en la Forma de Onda de Diente de Sierra Auditiva-Prime para extraer primero el contorno del tono y luego se utilizó un algoritmo MATLAB personalizado para calcular y derivar medidas de rango de tono y pendiente de tono. Resultados: El rango y la pendiente de tono se redujeron en algunos participantes con EP. Se observaron efectos de la edad y la duración de la enfermedad en personas con EP: reducciones en ambas medidas de tono con el aumento de la edad y la duración de la enfermedad. Conclusiones: Una nueva tarea de DDK de tono podría complementar la tarea DDK laríngea convencional en la evaluación y el tratamiento de trastornos motores del habla y de la voz. El análisis de la variabilidad individual podría proporcionar información específica de diagnóstico y terapéutica para personas con EP.
ABSTRACT
Abstract Background Parkinson's disease (PD) may progressively reduce the upper limb's functionality. Currently, there is no standardized upper limb functional capacity assessment in PD in the rehabilitation field. Objective To identify specific outcome measurements to assess upper limbs in PD and access functional capacity. Methods We systematically reviewed and analyzed the literature in English published from August/2012 to August/2022 according to PRISMA. The following keywords were used in our search: "upper limbs" OR "upper extremity" and "Parkinson's disease." Two researchers searched independently, including studies accordingly to our inclusion and exclusion criteria. Registered at PROSPERO CRD42021254486. Results We found 797 studies, and 50 were included in this review (n = 2.239 participants in H&Y stage 1-4). The most common upper limbs outcome measures found in the studies were: (i) UPDRS-III and MDS-UPDRS to assess the severity and progression of PD motor symptoms (tremor, bradykinesia, and rigidity) (ii) Nine Hole Peg Test and Purdue Pegboard Test to assess manual dexterity; (iii) Spiral test and Funnel test to provoke and assess freezing of upper limbs; (iv) Technology assessment such as wearables sensors, apps, and other device were also found. Conclusion We found evidence to support upper limb impairments assessments in PD. However, there is still a large shortage of specific tests to assess the functional capacity of the upper limbs. The upper limbs' functional capacity is insufficiently investigated during the clinical and rehabilitation examination due to a lack of specific outcome measures to assess functionality.
Resumo Antecedentes A doença de Parkinson (DP) reduz progressivamente a funcionalidade do membro superior. Não existe uma avaliação padronizada da capacidade funcional do membro superior na DP na área da reabilitação. Objetivo Identificar medidas de resultados específicos para avaliar membros superiores na DP e avaliar capacidade funcional. Métodos Revisamos e analisamos sistematicamente a literatura publicada de agosto/2012 a agosto/2022 de acordo com PRISMA. Usamos as seguintes palavras-chave "membros superiores" OU "extremidade superior" e "doença de Parkinson." Dois pesquisadores fizeram a busca de forma independente, incluindo estudos de acordo com os critérios de inclusão e exclusão. Registro PROSPERO CRD42021254486. Resultados Encontramos 797 estudos, 50 foram incluídos no estudo(n = 2.239 participantes no estágio 1-4 de H&Y). As medidas de resultados de membros superiores mais comuns encontradas foram: (i) UPDRS-III e MDS-UPDRS, para avaliar a gravidade e a progressão dos sintomas motores da DP (tremor, bradicinesia, e rigidez); (ii) Nine Hole Peg Test e Purdue Pegboard Test para avaliar a destreza manual; (iii) Teste da Espiral e Teste do Funil para provocar e avaliar o congelamento de membros superiores; (iv) Avaliação de tecnologia, como sensores vestíveis, aplicativos e outros dispositivos também foram encontrados. Conclusão Encontramos evidências para dar suporte para as avaliações de deficiências de membros superiores na DP. No entanto, ainda há grande escassez de testes específicos para avaliar a capacidade funcional dos membros superiores. A capacidade funcional dos membros superior é insuficientemente investigada durante o exame clínico e de reabilitação devido à falta de medidas de resultados específicos para avaliar a funcionalidade.
ABSTRACT
Resumen Objetivo: Determinar la latencia diagnóstica en la enfermedad de Parkinson (EP), así como su relación con variables clínicas y demográficas. Determinar la percepción de síntomas no motores: disfunción olfatoria, trastorno conductual del sueño MOR, depresión y estreñimiento, previos al diagnóstico de EP. Materiales y métodos: Estudio transversal realizado en Yucatán, México en sujetos con EP. Se analizó la asociación entre la latencia diagnóstica con variables clínicas y demográficas usando las pruebas estadísticas no paramétricas: U de Mann Whitney y Kruskal-Wallis. Resultados: Se incluyeron un total de 60 sujetos con una edad promedio de 66.7 años. El tiempo promedio transcurrido desde el inicio del primer síntoma motor hasta el diagnóstico fue de 20.8 meses. El tener antecedentes familiares de EP se asoció significativamente (p=0.031) con una latencia diagnóstica más prolongada en comparación con aquellos pacientes que no refirieron familiares con EP. En cualquier momento antes del diagnóstico de EP: el 36.6% de los pacientes percibieron estreñimiento, 15% depresión, 13.3% trastorno conductual del sueño MOR y 11.6% disfunción olfatoria, 51.7% no refirió ninguno. Conclusiones: La latencia diagnóstica promedio de un grupo de 60 pacientes con EP diagnosticados en Yucatán fue de 20.8 meses. La latencia diagnóstica no se asoció significativamente con el tipo de servicio médico de neurología que realizó en diagnóstico de EP (público o privado), ni con otras variables clínicas ni demográficas además del antecedente familiar de EP.
Abstract Objective: To determine the diagnostic latency in Parkinson's disease (PD), and its relationship with clinical and demographic variables. To determine the perception of non-motor symptoms: olfactory dysfunction, REM sleep behavior disorder, depression, and constipation, prior to the diagnosis of PD. Materials and methods: Cross-sectional study conducted in Yucatan, Mexico in subjects with PD. The association between diagnostic latency with clinical and demographic variables was analyzed using the non-parametric statistical tests: Mann Whitney U and Kruskal-Wallis. Results: A total of 60 subjects with a mean age of 66.7 years were included. The average time elapsed from the onset of the first sympoton to diagnosis was 20.8 months. A family history of PD was significantly associated (p=0.031) with a longer diagnostic latency compared to those patients who did not have relatives with PD. Before the diagnosis of PD: 36.6% of the patients perceived constipation, 15% depression, 13.3% REM sleep behavior disorder and 11.6% olfactory dysfunction, 51.7% did not report any. Conclusions: The mean diagnostic latency of a group of 60 patients with PD diagnosed in Yucatan was 20.8 months. Diagnostic latency was not significantly associated with the type of neurological medical service that performed the diagnosis (public or private), or with other clinical or demographic variables in addition to a family history of PD.
ABSTRACT
El SARS-CoV-2 fue registrada en la ciudad de Wuhan-China, por primera vez en diciembre de 2019. El impacto de esta nueva patología en pacientes con Enfermedad de Parkinson fue negativo, por cuanto puso al descubierto el desarrollo de complicaciones graves posteriores a esta infección, Además, el virus puede afectar indirectamente el sistema nervioso central a través de la respuesta inflamatoria y la liberación de citocinas, lo que puede tener un impacto negativo en la función neuronal, conduciendo a una mayor afectación en la calidad de vida de estos pacientes. Objetivo. Describir las complicaciones de la Enfermedad de Parkinson relacionadas con la infección por SARS-CoV-2. Metodología. Se realizó una revisión sistemática, a través de una búsqueda en bases de datos. En donde se incluyeron estudios publicados entre 2019 y 2022, que cumplan criterios de inclusión y exclusión, e informen sobre las complicaciones en pacientes con enfermedad de Parkinson. Resultados. Se procedió a la lectura de texto completo de cada artículo, siendo excluidos 13 artículos, debido a que no cumplían totalmente con criterios de inclusión, presentaban otra temática o tenían una metodología poco clara, resultados 17 como resultado. Conclusión. Es importante reconocer que el COVID-19 es una enfermedad multifacética que afecta principalmente al sistema respiratorio, pero también puede tener impactos en otros sistemas del cuerpo, incluido el sistema nervioso. Si bien se ha observado que algunos pacientes con Parkinson experimentan un empeoramiento de los síntomas motores y no motores durante la infección por COVID-19, entre los síntomas que más mayor prevalencia de complicaciones presentaron se encuentran las alteraciones del sueño, alteraciones del estado de ánimo, bradicinesia, rigidez, temblor, alteraciones de la marcha.
SARS-CoV-2 was recorded in Wuhan City-China for the first time in December 2019. The impact of this new pathology in patients with Parkinson's Disease was negative, in that it uncovered the development of severe complications following this infection, in addition, the virus may indirectly affect the central nervous system through inflammatory response and cytokine release, which may have a negative impact on neuronal function, leading to further impairment in the quality of life of these patients. Objective. To describe the complications of Parkinson's disease related to SARS-CoV-2 infection. Methodology. A systematic review was carried out through a database search. We included studies published between 2019 and 2022 that met inclusion and exclusion criteria and reported on complications in patients with Parkinson's disease. Results. We proceeded to read the full text of each article, being excluded 13 articles, because they did not fully meet inclusion criteria, presented another subject or had an unclear methodology, 17 as a result. Conclusion. It is important to recognize that COVID-19 is a multifaceted disease that primarily affects the respiratory system, but can also have impacts on other body systems, including the nervous system. While it has been observed that some Parkinson's patients experience worsening of motor and non-motor symptoms during COVID-19 infection, among the symptoms with the highest prevalence of complications were sleep disturbances, mood disturbances, bradykinesia, rigidity, tremor, gait disturbances.
O SARS-CoV-2 foi registrado na cidade de Wuhan, na China, pela primeira vez em dezembro de 2019. O impacto dessa nova patologia em pacientes com doença de Parkinson foi negativo, pois revelou o desenvolvimento de complicações graves após essa infecção. Além disso, o vírus pode afetar indiretamente o sistema nervoso central por meio da resposta inflamatória e da liberação de citocinas, o que pode ter um impacto negativo na função neuronal, levando a um maior comprometimento da qualidade de vida desses pacientes. Objetivo. Descrever as complicações da doença de Parkinson relacionadas à infecção pelo SARS-CoV-2. Metodologia. Foi realizada uma revisão sistemática por meio de uma pesquisa em banco de dados. Foram incluídos estudos publicados entre 2019 e 2022 que atenderam aos critérios de inclusão e exclusão e relataram complicações em pacientes com doença de Parkinson. Resultados. Prosseguimos com a leitura do texto completo de cada artigo e excluímos 13 artigos porque eles não atendiam totalmente aos critérios de inclusão, apresentavam um tópico diferente ou tinham uma metodologia pouco clara, resultados 17 Conclusão. É importante reconhecer que a COVID-19 é uma doença multifacetada que afeta principalmente o sistema respiratório, mas também pode ter impactos em outros sistemas do corpo, incluindo o sistema nervoso. Embora alguns pacientes com Parkinson tenham apresentado piora dos sintomas motores e não motores durante a infecção por COVID-19, os sintomas com maior prevalência de complicações incluem distúrbios do sono, distúrbios do humor, bradicinesia, rigidez, tremor e distúrbios da marcha.
ABSTRACT
Introdução: O envelhecimento e a presença de doenças crônicas como a Doença de Parkinson (DP) podem gerar incapacidade e afetar a vida da pessoa, sendo que a Classificação Internacional de Funcionalidade, Incapacidade e Saúde (CIF), na perspectiva biopsicossocial, permite conhecer a funcionalidade na DP. Objetivo: Investigar a funcionalidade de pessoas com Doença de Parkinson em atendimento fonoaudiológico grupal, tomando a CIF como base conceitual. Método: Pesquisa transversal, aprovada pelo CEP, com 10 participantes com DP, em atendimento fonoaudiológico grupal. Foi elaborado roteiro de entrevista para coleta do perfil sociodemográfico e questionário autoaplicável para coleta da autopercepção nas categorias da CIF em entrevistas com os participantes em três encontros grupais videogravados, com duração de 35 minutos cada. Para estabelecimento de parâmetros de referência, duas juízas fonoaudiólogas classificaram as respostas nas mesmas categorias. Resultados: Os participantes relataram prejuízos em Funções do Corpo (voz, articulação, fluência e do ritmo da fala, movimentos involuntários), dificuldades em Atividades e Participação (fala, conversação, uso fino da mão, andar, vestir-se, realização de tarefas domésticas, e recreação e lazer) e barreiras nos Fatores Ambientais. Em 60% dos casos a concordância entre participantes e juízas foi discreta, 30% regular, e em um caso (10%) foi forte. Conclusão: Os resultados mostram as dificuldades de linguagem e de funcionalidade na percepção das próprias pessoas com DP, conferindo um caráter original à pesquisa por dar voz a elas e trazer subsídios para o cuidado centrado na pessoa, transpondo, assim, a visão biomédica da atenção centrada na doença. (AU)
ntroduction: Aging and the presence of chronic diseases such as Parkinson's Disease (PD) can generate disability and affect a person's life, and the International Classification of Functioning, Disability and Health (ICF), from a biopsychosocial perspective, allows studying the functioning in PD. Objective: To investigate the functioning of people with PD in a speech-language pathology (SLP) group, taking the ICF as a conceptual basis. Method: Cross-sectional study, approved by the Ethics Committee, with 10 participants with PD, in SLP group. An interview script was developed to collect the sociodemographic profile and a self-administered questionnaire to collect self- perception in the ICF categories in interviews with participants in three videotaped group meetings, lasting 35 minutes each. To establish a reference parameter, two SLP with experience in the ICF (judges) classified the answers in the same categories. Results: Participants reported impairments in Body Functions (voice, articulation, fluency and rhythm of speech, involuntary movements), difficulties in Activities and Participation (speech, conversation, fine use of the hand, walking, dressing, performing household chores, and recreation and leisure) and barriers in Environmental Factors. In 60% of the cases, the agreement between participants and judges was slight, 30% regular, and in one case (10%) it was strong. Conclusion: The results showed language and functioning difficulties in the perception of people with PD, giving an original character to the research by giving them a voice and bringing subsidies to person-centered care, thus transposing the biomedical view of disease-centered care. (AU)
Introducción: El envejecimiento y la presencia de enfermedades crónicas como la Enfermedad de Parkinson (EP) pueden generar incapacidad y afectar a la vida de la persona, siendo que en la Clasificación Internacional del Funcionamiento, Incapacidad y Salud (CIF), en la perspectiva biopsicosocial, permite conocer el funcionamiento en la EP. Objetivo: Investigar el funcionamiento de personas con EP en la intervención fonoaudiológica grupal, tomando la CIF como base conceptual. Método: Estudio transversal aprobado por el CEP (Comité de Ética) con 10 participantes con EP, en tratamiento fonoaudilógico grupal. Se elaboró un guion de entrevista para colección de perfil sociodemográfico y un cuestionario autoaplicable para recopilar la autopercepción en las categorías de la CIF en entrevistas con los participantes en tres encuentros grupales videograbados, con una duración promedio de 35 minutos cada uno. Para establecer parámetros de referencia, dos juezas fonoaudiólogas clasificaron las respuestas en las mismas categorías. Resultados: Los participantes informaron déficit en las Funciones del Cuerpo (voz, articulación, fluidez y ritmo del habla, movimientos involuntarios), dificultades en las Actividades y Participación (habla, conversación, uso fino de la mano, caminar, vestirse, realizar las tareas domésticas, y recreación y ocio) y barreras en Factores Ambientales. En el 60% de los casos la concordancia entre participantes y juezas fue discreta, en el 30% fue regular y en un caso (10%) fue fuerte. Conclusión: Los resultados mostraron las dificultades de lenguaje y funcionamiento en la percepción de las propias personas con EP, dando un carácter original al estudio por darles voz y traer subsidios para el cuidado centrado en la persona, transponiendo así, la visión biomédica de la atención centrada en la enfermedad. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Parkinson Disease , International Classification of Functioning, Disability and Health , Diagnostic Self Evaluation , Cross-Sectional Studies , Surveys and Questionnaires , Health of the Disabled , Speech Sound Disorder , Physical Functional Performance , Models, Biopsychosocial , Group PracticeABSTRACT
Introduction: Falls are common in Parkinson's disease (PD), happening to up to 68% of these individuals. Patients with PD present motor and gait impairment that increase the fall risks by three times. This study aimed to compare cognitive impairment and the occurrence of falls in PD patients. Methods: Retrospective and cross-sectional study through data collection in electronic medical records searching for the occurrence of falls (dichotomous and coded responses: 1=yes and 2=no) in the period of up to three months of cognitive assessment. For data analysis, descriptive statistics, and inferential analyses (Mann-Whitney U Test) were performed to compare the cognitive tests' scores between the two groups (who answered Yes/fallers and non-fallers). A significance level of p<0.05 was adopted. Results: There was no difference between the subgroups (fallers=23; non-fallers=60) regarding age (p=0.28), schooling (0.51) and years of disease progression (0.99). No difference was observed between the subgroups for most cognitive variables, except Trail Making Test (B and delta). There was a tendency to differ in Addenbrooke's cognitive examination III (ACE-III) (total and attention and memory domains), with lower performance for the fallers subgroup. Worse functionality and more frequent cognitive issues were observed in those with reported falls. Conclusion: It was observed that cognitive measures, especially attentional and memory measures, interfere with episodes of falls in patients with PD. It is necessary to increase the sample and balance between the subgroups for further evidence of these results.
Introdução: As quedas são comuns na doença de Parkinson (DP), ocorrendo em até 68% desses indivíduos. Pacientes com DP apresentam comprometimento motor e da marcha que aumentam em três vezes o risco de quedas. Este estudo teve como objetivo comparar o comprometimento cognitivo e a ocorrência de quedas em pacientes com DP. Métodos: Estudo retrospectivo e de corte transversal, por meio de coleta de dados em prontuário eletrônico sobre ocorrência de quedas (respostas dicotômicas e codificadas: 1=sim e 2=não) no período de até três meses da avaliação cognitiva. Para análise dos dados, foram realizadas estatísticas descritivas e inferenciais (Mann-Whitney U Test) para comparar os escores dos testes cognitivos entre os dois grupos (que responderam Sim/caem e Não/não caem). Foi considerado nível de significância de p<0,05. Resultados: Não houve diferença entre os subgrupos (caidores=23; não caidores=60) quanto à idade (p=0,28), escolaridade (0,51) e anos de evolução da doença (0,99). Nenhuma diferença foi observada entre os subgrupos para a maioria das variáveis cognitivas, exceto Teste de Trilhas (B e delta). Houve uma tendência de diferença Exame cognitivo de Addenbrooke III (ACE-III) (domínios total e atenção e memória), com desempenho inferior para o subgrupo de caidores. Pior funcionalidade e problemas cognitivos mais frequentes foram observados naqueles com quedas relatadas. Conclusão: Observou-se que medidas cognitivas, principalmente atencionais e de memória, interferem nos episódios de quedas em pacientes com DP. É necessário aumentar a amostra e o equilíbrio entre os subgrupos para maior comprovação destes resultados.
ABSTRACT
Trata-se de um estudo transversal retrospectivo que incluiu 27 pessoas com doença de Parkinson (DP), diagnosticados por neurologista. O objetivo do estudo foi analisar o tipo de correlação entre o grau de comprometimento motor e grau de depressão em pessoas com DP, tendo como hipótese que quanto maior o grau de comprometimento motor proporcionado pela doença, maior o grau de depressão. Foram utilizados os instrumentos Inventário de Depressão de Beck (BDI II) para a medida de sintomas depressivos e do grau de depressão, e a escala Hoehn & Yahr foi aplicada para identificação do grau de comprometimento motor. Foram excluídos indivíduos que não preencheram um dos instrumentos do estudo, selecionando apenas as pessoas com DP que preencheram ambos os instrumentos. Verificou-se uma correlação positiva e significativa entre os resultados do BDI -II e a escala Hoehn & Yahr modificada (r = 0,41, p = 0,035). O estudo identificou, portanto, uma associação crescente e positiva entre o grau de comprometimento motor das pessoas com DP e a presença de sintomas de depressão. Com isso, foi possível concluir que, uma pessoa com DP e maior grau de comprometimento motor, tende a apresentar maior número de sintomas depressivos e, consequentemente maior grau de depressão e vice-versa. Portanto, deve-se dedicar maior atenção à saúde mental dos casos em que a doença se expressa com maior comprometimento motor.
This is a retrospective cross-sectional study that included 27 people with Parkinson's disease (PD), diagnosed by a neurologist. The objective of the study was to analyze the type of correlation between the degree of physical impairment and degree of depression in people with PD, having as hypothesis that the greater the degree of physical impairment provided by the disease, the greater the degree of depression. The Beck Depression Inventory (BDI II) was used to measure depressive symptoms and the degree of depression, and the modified Hoehn & Yahr scale was applied to identify the degree of physical impairment. Individuals who did not complete one of the study instruments were excluded, selecting only those people with PD who completed both instruments. A positive and significant correlation can be verified between the results of the BDI -II and the Hoehn & Yahr scale (r = 0.41, p = 0.035). The study identified, therefore, an increasing and positive association between the degree of motor impairment of people with PD and the presence of symptoms of depression. With this, it was possible to conclude that, a person with PD and a higher degree of motor impairment, tends to present a higher number of depressive symptoms and, consequently, a higher level of depression and vice versa. Thus, the more physically compromised the person with PD is, the greater the association with a more severe depression. Therefore, greater attention should be paid to mental health in cases in which the disease is expressed with greater physical impairment.
ABSTRACT
La composición química del aceite de oliva extra virgen (AOEV) se compone principalmente de triglicéridos, ácidos grasos insaturados como ácido oleico, ácido linoleico y el α-linolénico. También se destacan compuestos fenólicos de tres clases químicas: simples, secoiridoides y lignanos. En la presente revisión se analizó el consumo del AOEV en enfermedades crónicas, ciertos tipos de cáncer y en enfermedades neurodegenerativas. La evidencia muestra que el consumo de entre 8 y 40 g de AOEV diario tiene efectos protectores en enfermedades cardiovasculares, puede evitar la aparición de diabetes tipo 2 y aumentar los niveles de colesterol HDL. Respecto al cáncer, entre los efectos evaluados se destacan los encontrados a partir de los compuestos fenólicos hidroxitirosol (HT) y oleocantal, los que han demostrado un efecto protector en algunos tipos de cáncer como cáncer de piel y de mama. En las enfermedades neurodegenerativas, se observó que el consumo diario de 50 g de AOEV, tiene un efecto inhibidor en la degeneración neuronal atribuido a sus compuestos fenólicos como oleuropeina e HT. Investigaciones a futuro debieran enfocarse en determinar los efectos a largo plazo del consumo de AOEV en las diferentes enfermedades analizadas, para así poder ir estableciendo la "dosis" de AOEV que permita obtener resultados protectores sobre la salud. Además de explorar los efectos de las diferentes variedades de aceitunas (con sus componentes bioactivos particulares) con el fin de establecer los efectos en la salud y enfermedad asociados a variedades específicas.
The chemical composition of extra virgin olive oil (EVOO) is mainly composed of triglycerides, unsaturated fatty acids such as oleic acid, linoleic acid, and α-linolenic acid. Phenolic compounds of three chemical classes are also relevant, such as simple, secoiridoids, and lignans. Here, we review the association between EVOO consumption and chronic diseases, certain types of cancer, and neurodegenerative diseases. Evidence shows that consuming between 8 and 40 g of EVOO / day has protective effects on cardiovascular diseases, can prevent the onset of type 2 diabetes, and increases HDL cholesterol levels. Regarding cancer, phenolic compounds hydroxytyrosol (HT) and oleocanthal have protective effects on some types of cancer, such as skin and breast cancer. Regarding neurodegenerative diseases, daily consumption of phenolic compounds such as oleuperin and hydroxytyrosol and 50 g of EVOO has an inhibitory effect on neuronal degeneration and a protective effect on neuroprotective capacity. Future research should focus on determining the long-term impact of EVOO consumption on different diseases to establish the "dose" of EVOO that will allow health-protective results. It is also necessary to establish the effects of the specific olives (with their particular bioactive components) to establish the different impacts on health and disease associated with olives varieties.
ABSTRACT
Ashwagandha - Withania somnifera (L.) Dunal is a perennial shrub belonging to the family Solanaceae. Ashwagandha has been used for over 3000 years in traditional Indian Ayurveda for treatment of various neurological, and stress disorders. The root of Ashwagandha (ASH) is regarded as a tonic, aphrodisiac, narcotic, diuretic, anthelmintic, astringent, thermogenic and stimulant. Ashwagandha with other herbal decoctions was recognized to treat Kampavatha (Parkinson’s Disease) since 18th century. With this wide array of ethnopharmacological relevance, Ashwagandha has been recognized as one of the prominent complementary and alternative medicine to treat many neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s disease (PD). There is a prominent increase in the cases of AD and PD all over the world and it demands the requirement of complementary and alternative herbal remedies with no/minimal side effects. Many genetic factors are responsible for the onset and progression of PD. Loss-of-function mutations in the parkin gene are a major cause of early onset of autosomal recessive juvenile parkinsonism (AR-JP). Drosophila park25 loss of function mutants exhibit significantly increased number of mitochondria-endoplasmic reticulum contacts and a significantly decreased number of dopaminergic neurons in the adult brain which is the main cause of PD condition. Several studies have demonstrated the ability of Ashwagandha in imparting neuroprotection, improved locomotory ability, memory and learning abilities. The challenge lies in scrutinizing the mechanism and the pathways involved in the neuroprotective properties of this well-known herb. Here in our study, we test the possible neuroprotective effect of Ashwagandha on park25 mutants of Drosophila using lifespan analysis and climbing disability as a disease marker. Parkinson’s mimicking flies were administered with aqueous extraction of Ashwagandha-root mixed with the fly food and subjected to negative geotaxis assay. We observed that there is a prominent increase in the climbing ability in park25 treated flies compared to its age-matched untreated flies. This is the first report showing that, aqueous extraction of Ashwagandha-root extract was able to ameliorate the disease phenotype in the park25 Drosophila Parkinson’s disease model.
ABSTRACT
La acupuntura es una técnica muy eficaz y segura para el tratamiento de los síntomas de la enfermedad de Parkinson. La práctica de esta técnica tiene entre sus beneficios: disminuir los signos y síntomas, mejorar las funciones motoras, reducir la necesidad de medicación, minimizar los efectos secundarios de la medicación, ralentizar la evolución de la enfermedad, aumentar los niveles de dopamina, disminuir el daño y la muerte neuronal, aumentar los niveles de ciclofilina, incrementar el número de células madre y el número de neuronas transformadas de ellas y potenciar los sistemas antioxidantes. Desde hace años se ha venido postulando que la inserción de agujas provoca la liberación de endorfinas y que promueve el flujo sanguíneo local.
Acupuncture is a very effective and safe technique for treating the symptoms of Parkinson's disease. The practice of this technique has among its benefits: reducing signs and symptoms, improving motor functions, reducing the need for medication, minimizing medication side effects, slowing the progression of the disease, increasing dopamine levels, decreasing neuronal damage and death, increase cyclophilin levels, increase the number of stem cells and the number of neurons transformed from them, and enhance antioxidant systems. For years it has been postulated that the insertion of needles causes the release of endorphins and that it promotes local blood flow.
ABSTRACT
Abstract Background Performing motor evaluations using videoconferencing for patients with Parkinson's disease (PD) is safe and feasible. However, the feasibility of these evaluations is not adequately studied in resource-limited settings. Objective To evaluate the feasibility of performing motor evaluations for patients with PD in a resource-limited setting. Methods The examiners rated motor aspects of parkinsonism of 34 patients with PD from the Brazilian public healthcare system through telemedicine with the patient's own means by using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating scale. Quality measures of the video meeting were also obtained. The feasibility of rating the motor aspects was the primary outcome whereas the rating of individual motor aspects, video meeting quality and predictors of a complete evaluation served as secondary outcomes. Results The least assessable parameters were freezing of gait (52.9%), gait (70.6%), leg agility, and rest tremor (both 76.5%). Complete MDS-UPDRS part III was possible in 41.2% of patients and 62 out of 374 motor aspects evaluated (16.6%) were missed. Available physical space for a video evaluation was the worst quality measure. Incomplete evaluations were directly associated with disability (p = 0.048, r = 0.34) and inversely with available physical space (p = 0.003, r = 0.55). Conclusion A significant portion of the MDS-UPDRS part III is unable to be performed during telemedicine-based evaluations in a real-life scenario of a resource-limited setting.
Resumo Antecedentes Realizar avaliações motoras usando videoconferência para pacientes com doença de Parkinson (DP) é seguro e viável. Entretanto, a viabilidade dessas avaliações não é adequadamente estudada em cenários com recursos limitados. Objetivo Identificar a viabilidade de realizar avaliações motoras para pacientes com DP em um ambiente com recursos limitados. Métodos Os examinadores avaliaram os aspectos motores da DP de 34 pacientes do sistema público de saúde brasileiro através da telemedicina com os próprios meios do paciente usando a escala Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Medidas de qualidade da videochamada também foram obtidas. A viabilidade da classificação dos aspectos motores foi o resultado primário, enquanto a classificação dos aspectos motores individuais, a qualidade das videoconferências e os preditores de uma avaliação completa serviram como resultados secundários. Resultados Os parâmetros menos avaliáveis foram congelamento da marcha (52,9%), marcha (70,6%), agilidade dos membros inferiores e tremor de repouso (ambos 76,5%). A parte III completa da MDS-UPDRS foi possível em 41,2% dos pacientes, mas não foi possível avaliar 62 do total de 374 aspectos motores (16,6%). O espaço físico disponível para uma avaliação em vídeo foi a pior medida de qualidade. As avaliações incompletas foram diretamente associadas ao nível de dependência (p = 0,048, r = 0,34) e inversamente ao espaço físico disponível (p = 0,003, r = 0,55). Conclusão Uma porção significativa da parte III da MDS-UPDRS é perdida durante as avaliações baseadas em telemedicina em um cenário da vida real com recursos limitados.
ABSTRACT
Abstract Background Levodopa-induced dyskinesia (LID) is a common motor complication of levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used and inexpensive tetracycline with anti-inflammatory properties. Objective To evaluate the efficacy and safety of doxycycline in patients with PD and LID. Methods This was an open-label, uncontrolled, single-arm, single-center, phase 2 proof-of-concept study in patients with PD with functional impact of dyskinesia, which used levodopa three times daily, in a movement disorders clinic in Brazil. Participants were treated with doxycycline 200 mg/day for 12 weeks, with evaluations at baseline, week4, and week 12 of treatment. The primary outcome measure was the change from baseline in the Unified Dyskinesia Rating Scale (UDysRS) total score at week 12, evaluated by two blinded raters. Key secondary outcomes measures were OFF time and ON time with troublesome dyskinesia in the PD home diary. Results Eight patients with PD were treated and evaluated. Doxycycline 200 mg/day reduced the UDysRS total score at week 12, compared with baseline (Friedman χ2 = 9.6; p = 0.008). Further, doxycycline reduced the ON time with troublesome dyskinesia (Friedman χ2 = 10.8; p = 0.004) without worsening parkinsonism. There were no severe adverse events, and dyspepsia was the commonest event. Conclusion In this preliminary, open-label and uncontrolled trial, doxycycline was effective in reducing LID and safe after a 12-week treatment. Further well-designed placebo-controlled clinical trials with a longer duration and a larger number of participants are needed. Clinical trial registration https://ensaiosclinicos.gov.br, identifier: RBR-1047fwbf
Resumo Antecedentes A discinesia induzida por levodopa (DIL) é uma complicação motora comum da terapia com levodopa em pacientes com doença de Parkinson (DP). A doxiciclina é uma tetraciclina amplamente usada e barata, com propriedade anti-inflamatória. Objetivo Avaliar a eficácia e segurança da doxiciclina em pacientes com DP e DIL. Métodos Este foi um estudo aberto, não-controlado, de braço único, monocêntrico, fase 2 e de prova de conceito, em pacientes com DP e impacto funcional das discinesias, que usavam levodopa três vezes ao dia, em um ambulatório de distúrbios de movimento no Brasil. Os participantes foram tratados com doxiciclina 200 mg/dia por 12 semanas, com avaliações na base, na semana 4 e na semana 12 do tratamento. A medida de desfecho primário foi a mudança no escore total da Unified Dyskinesia Rating Scale (UDysRS) da base à semana 12, avaliada por dois avaliadores cegos. As medidas-chave de desfecho secundário fora o tempo em OFF e tempo em ON com discinesia problemática. Resultados Oito pacientes com DP foram tratados e avaliados. A doxiciclina 200 mg/dia reduziu o escore total da UDysRS na semana 12, comparado com a avaliação inicial (χ2 de Friedman = 9.6; p = 0.008). Além disso, a doxiciclina reduziu o tempo em ON com discinesia problemática (χ2 de Friedman = 10.8; p = 0.004) sem piorar o parkinsonismo. Não houve eventos adversos graves, e dispepsia foi o evento mais comum. Conclusão No presente estudo preliminar, aberto e não-controlado, a doxiciclina foi eficaz em reduzir as DIL e segura após tratamento por 12 semanas. Estudos clínicos bem-desenhados e placebo-controlados adicionais, com duração mais longa e maior número de participantes, são necessários.
ABSTRACT
Abstract Background Cell phones are part of peoples' lives. The literature indicates risks when cell phones are used during a secondary motor task. Studies addressing this topic in people with Parkinson's disease are still scarce. Objective To investigate the impact of daily dual tasks with cell phone on balance and mobility in people with Parkinson's disease, compared to healthy control peers. Methods Participants with Parkinson's disease and controls underwent three motor tasks: (1) Standing and walking without using a cell phone; (2) Standing and walking while talking on the phone; and (3) Standing and walking while texting messages on the phone. Assessments involved balance and mobility tests. Statistical analysis was performed with multivariate analysis of variance, comparing main effect for group (Parkinson's disease × control), task (using × not using cell phone) and interactions (group × task). Significance was set at 5%. Effect sizes are reported. Results Participants with Parkinson's disease showed worse balance (p = 0.001, effect size of 0.471) and mobility (p = 0.001, effect size of 0.472) than control peers. The use of cell phone while performing a secondary motor task affected both groups (p = 0.005, effect size of 0.673 for balance and p = 0.001, effect size of 0.549 for mobility). The dual task impact, however, was higher in the Parkinson's disease group (p = 0.009, effect size of 0.407 for mobility). Conclusion Daily dual tasks with cell phones increase imbalance and mobility risks in Parkinson's disease. People should be careful when using their cell phone while standing or walking.
Resumo Antecedentes Aparelhos celulares fazem parte da vida das pessoas. A literatura aponta riscos quando o uso do celular está associado a uma tarefa motora. Estudos abordando esse tema na doença de Parkinson são escassos. Objetivo Investigar o impacto de tarefas-duplas com o celular sobre equilíbrio e mobilidade de pessoas com doença de Parkinson, na comparação com controles saudáveis. Métodos Participantes com e sem doença de Parkinson foram submetidos a três tarefas: (1) Ficar em pé e caminhar sem o celular; (2) Ficar em pé e caminhar enquanto conversa ao celular; e (3) Ficar em pé e caminhar enquanto digita mensagens. As avaliações envolveram testes de equilíbrio e mobilidade. Os procedimentos estatísticos envolveram testes de análise múltipla de variâncias, com análise de efeito principal para os fatores grupo (doença de Parkinson x controle), tarefa (com celular × sem celular) e interação (grupo × tarefa). Significância foi estipulada em 5%. Tamanhos de efeito foram reportados. Resultados Participantes com doença de Parkinson apresentaram pior equilíbrio (p = 0,001; tamanho do efeito: 0,471) e mobilidade (p = 0,001; tamanho do efeito: 0,472) que controles. O uso do celular afetou ambos os grupos (p = 0,005, tamanho do efeito de 0,673 para equilíbrio e p = 0,001, tamanho do efeito de 0,549 para mobilidade). O impacto da tarefa-dupla, contudo, foi maior no grupo Parkinson (p = 0,009; tamanho do efeito de 0,407 para mobilidade). Conclusão Tarefas simultâneas com o celular causam desequilíbrio e problemas de mobilidade na doença de Parkinson. As pessoas devem ter cuidado ao utilizar celulares durante atividades em pé e ao caminhar.